Real-World Evidence: Shaping Obesity Treatment Beyond Clinical Trials

Amgen’s research reveals that real-world evidence provides critical insights into how obesity medications perform outside controlled clinical trials. The company found that upwards of 50 to 60% of patients discontinue long-term obesity therapy, with many experiencing significant weight regain after stopping treatment. By leveraging electronic health records, claims data, and expanding partnerships with telehealth providers, Amgen aims to better understand treatment adherence patterns and patient needs in everyday care settings.